Key result
Dabigatran is linked to lower acute kidney injury risk compared with warfarin in Asian NVAF.
Why the study?
Whether dabigatran is associated with a lower risk of acute kidney injury than warfarin in Asian patients with nonvalvular atrial fibrillation remained unknown.
Does dabigatran reduce the risk of acute kidney injury compared to warfarin in Asian patients with nonvalvular atrial fibrillation?
Cohort (n=19,932)
Yes
Does dabigatran reduce the risk of acute kidney injury compared to warfarin in Asian patients with nonvalvular atrial fibrillation?
In Asian patients with nonvalvular atrial fibrillation, dabigatran is associated with a lower risk of acute kidney injury compared to warfarin.
Answers are grounded in this paper and cite their sources.
May inform anticoagulant choice to lower AKI risk in Asian NVAF patients; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Whether dabigatran is associated with a lower risk of acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown. OBJECTIVES: The authors compared the risk of AKI in Asians with NVAF who were prescribed dabigatran versus warfarin. METHODS: The authors analyzed patients enrolled in the Taiwan nationwide retrospective cohort study from June 1, 2012, to December 31, 2013. Dabigatran and warfarin were taken by 7,702 and 7,885 NVAF patients without a history of chronic kidney disease (CKD) and 2,256 and 2,089 NVAF patients with a history of CKD, respectively. A propensity-score weighted method was used to balance covariates across study groups. CONCLUSIONS: Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than warfarin.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2016) conducted a cohort in Nonvalvular atrial fibrillation (n=19,932). Dabigatran vs. Warfarin was evaluated on Acute kidney injury (AKI). Dabigatran was associated with a lower risk of acute kidney injury compared with warfarin in 19,932 Asian patients with nonvalvular atrial fibrillation, including those with CHA2DS2-VASc ≥4 or HAS-BLED ≥3.
Synapse has enriched 10 related papers. Consider them for comparative context: